This article is available to subscribers. Sign in or Subscribe.

Original ArticleFree PreviewArchive

Platelet Function in Essential Thrombocythemia — Decreased Epinephrine Responsiveness Associated with a Deficiency of Platelet α-Adrenergic Receptors

  • Paul Kaywin, M.D.,
  • Margaret McDonough,
  • Paul A. Insel, M.D.,
  • and Sanford J. Shattil, M.D.

Abstract

Platelets from two patients with essential thrombocythemia failed to aggregate or release serotonin in response to concentrations of epinephrine that aggregated platelets from normal controls. Therefore, we studied their α-adrenergic receptors, using 3H-dihydroergocryptine (3H-DHE), an α-adrenergic antagonist. These platelets contained an average (mean ± S.E.) of 210±18 and 227±27 3H-DHE binding sites per platelet — less than half that found on control platelets, 464±37 (P<0.01). In contrast, platelets from two other patients with essential thrombocythemia responded to epinephrine and contained a normal number of 3H-DHE sites. Platelets in essential thrombocythemia demonstrated normal kinetics of 3H-DHE binding and normal affinities for 3H-DHE and for epinephrine. When control platelets were preincubated with a half-saturating concentration of 3H-DHE, there was a diminution of epinephrine-induced platelet function comparable to that seen in essential thrombocythemia. Thus, a deficiency of α-adrenergic receptors may account for diminished functional responsiveness of platelets to epinephrine in some patients with essential thrombocythemia. (N Engl J Med 299:505–509, 1978)

Funding and Disclosures

Supported by a grant (HL-16496) from the National Institutes of Health and by grants from the U.S. Veterans Administration and the American Heart Association (Dr. Insel is an established investigator of the American Heart Association, and Dr. Shattil a clinical investigator of the Veterans Administration).

We are indebted to Dr. Manfred Goldwein for permission to study his patient and to Dr. Richard A. Cooper for suggestions and a review of the manuscript.

Author Affiliations

From the Hematology-Oncology Section, Department of Medicine, University of Pennsylvania School of Medicine, the Philadelphia Veterans Administration Hospital and the Division of Clinical Pharmacology, departments of Medicine and Pharmacology, University of California, San Francisco (address reprint requests to Dr. Shattil at the Philadelphia Veterans Administration Hospital, University and Woodland Aves., Philadelphia, PA 19104).

Purchase this article
Print Subscriber? Activate your online access.